Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 28, Number 8—August 2022

Research

Characterization of Emerging Serotype 19A Pneumococcal Strains in Invasive Disease and Carriage, Belgium

Stefanie DesmetComments to Author , Heidi Theeten, Lies Laenen, Lize Cuypers, Piet Maes, Wouter Bossuyt, Liesbet Van Heirstraeten, Willy E. Peetermans, and Katrien Lagrou
Author affiliations: University Hospitals Leuven, Leuven, Belgium (S. Desmet, L. Laenen, L. Cuypers, W. Bossuyt, W.E. Peetermans, K. Lagrou); Katholieke Universiteit Leuven, Leuven (S. Desmet, P. Maes, W. Bossuyt, W.E. Peetermans, K. Lagrou); University of Antwerp, Antwerp, Belgium (H. Theeten, L. Van Heirstraeten); Katholieke Universiteit Leuven‒University Hospitals Leuven, Leuven (W. Bossuyt)

Main Article

Table 1

Characteristics and antimicrobial drug susceptibility for serotype 19A strains of pneumococci isolated during the period after the PCV13 to PCV10 switch, Belgium*

Characteristic IPD, young children IPD, older persons Carriage, young children Total
No. strains
 54
 56
 56
 166
Year of isolation
 2017–2018
 2018
 2017–2018
 2017–2018
Age
0–11 mo 41 0 8 49
13–23 mo 13 0 32 45
2–3 y 0 0 15 15
3–4 y 0 0 1 1
65–85 y
 0
 56
 0
 56
Sex, M/F
 32/22
 27/29
 28/28
 87
Source of isolation
Blood 48 56 0 104
CSF 5 0 0 5
Pleural fluid 1 0 0 1
Nasopharyngeal swab specimen
 0
 0
 56
 56
Penicillin resistant 7 (13.0) 5 (11.1) 3 (5.4) 15 (9.0)
Levofloxacin resistant 0 (0) 0 (0) 0 (0) 0 (0)
Erythromycin resistant 16 (29.6) 10 (17.9) 13 (23.2) 39 (23.5)
Tetracycline resistant
 15 (27.8)
 10 (17.9)
 12 (21.4)
 37 (22.3)
Pilus 1 25 (46.3) 27 (48.2) 27 (48.2) 79 (47.6)
Pilus 1 and pilus 2 3 (5.6) 2 (3.6) 4 (7.1) 9 (5.4)

*Values are no. or no. (%). CSF, cerebrospinal fluid; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.

Main Article

Page created: May 22, 2022
Page updated: July 20, 2022
Page reviewed: July 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external